Renal Biomarkers Market To Find Better Growth with US$ 1,894.2 Million By 2027 | CAGR: 7.6%: Coherent Market Insights
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The increasing incidence of various kidney disorders such as acute kidney injury (AKI), chronic kidney disease (CKD), nephropathies, and drug-induced kidney toxicities has led to development of novel renal biomarkers to regulate disease progression rate. Renal biomarkers are utilized to localize kidney injury (i.e., at the glomerular level, tubular level, or both) and differentiate renal injury from pre-, post-, and non-renal injury. These biomarkers also aids in predicting severity of renal injury and monitor the effects of intervention. These aforementioned factors are expected to drive the market growth over the forecast period.
The global renal biomarkers market is estimated to be valued at US$ 1,094.5 Mn in 2019 and is expected to reach over US$ 1,894.2 Mn by the end of 2027.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/3551
Global Renal Biomarkers Market: Drivers
The growth of the market is attributed to growing demand for early diseases diagnosis of various kidney diseases, among populace, which has driven demand for renal biomarkers over the forecast period. Renal biomarkers offer early diagnosis of kidney injury and provide better information about the status of ongoing injury in patients with chronic kidney disease. These biomarkers also predict the probability of progression of disease, which aids in development of personalized medicine, indicated for the treatment of chronic kidney disease.
Global Renal Biomarkers Market: Opportunities
Moreover, increasing application of renal biomarkers for the diagnosis of renal cancer is expected to offer lucrative growth opportunities for players operating in the global renal biomarkers market over the forecast period. Renal biomarkers play an important in diagnosis of renal cancer. Currently many clinical and laboratory algorithms are being used but there is no perfect tool for early diagnosis of renal cancer and tumors, that are thought to be accidently detected during routine abdominal imaging.
Browse Press Release: https://www.coherentmarketinsights.com/press-release/renal-biomarkers-market-2870
Global Renal Biomarkers Market: Restraints
However, lack in validation of novel renal biomarkers and their failure to correlate with clinical outcomes are some of the prime factors that are expected to hamper growth of the global biomarkers market over the forecast period. Majority of renal biomarkers currently in use elevate too late, hence cannot be easily co-related with biologic or clinical outcomes. Moreover, renal biomarkers available today are indicative of renal function and are affected by non-renal parameters such as gender, age, and medication status, which makes it more difficult to control acute kidney injury (AKI).
Among biomarker type, functional biomarkers segment in the global renal biomarkers market was valued at US$ 543.6 Mn in 2018 and is expected to reach US$ 1,057.3 Mn by 2027 exhibiting a CAGR of 7.6% over the forecast period. The segment growth is attributed to increasing products, and assay launches. For instance, Sphingotec launched penKid point-of-care (POC) biomarker blood test for evaluating kidney function in January 2020 in CE mark accepted European countries
On the basis of technique, enzyme linked immunosorbent assay segment held a dominant position in the global renal biomarkers market in 2018, accounting for 44.3% market share in terms of value, followed by Particle-Enhanced Turbidimetric Immunoassay and Colorimetric Assay segments, respectively. The segment growth is attributed to increasing applications of enzyme linked immunosorbent assay (ELISA) to identify proteins, peptides, antibodies, and hormones. Moreover, majority of kidney biomarker tests involve application of enzyme linked immunosorbent assay technique that is further expected to drive growth of the segment over the forecast period.
Among end user, diagnostic labs segment held a dominant position in the global renal biomarkers market in 2018, accounting for 34.9% market share in terms of value, followed by outpatient clinics and research centers segments, respectively. Diagnostic laboratories is the primary end user where kidney biomarker tests are performed in bulk. Physicians often recommend kidney disease patients to have diagnostic tests performed in central diagnostic laboratories. These aforementioned factors are expected to drive the market growth over the forecast period.
Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/3551
Moreover, several government organizations are offering grants for R&D in renal diseases. For instance, in September 2018, the National Institute of Diabetes and Digestive and Kidney Diseases, a part of Department of Health and Human Services – National Institutes of Health, awarded Yale University a grant for ‘Identification of Non-invasive Biomarkers and Indices for Diagnosis of Drug-Induced Acute Interstitial Nephritis.
Furthermore, R&D of biomarkers for kidney allergic reaction is expected to drive growth of the market over the forecast period. For instance, in May 2019, researchers from Johns Hopkins Medicine (U.S) reported identifying two protein biomarkers in urine, Urine TNF-α and IL-9’, for effective diagnosis of acute interstitial nephritis.
Global Renal Biomarkers Market: Competitive Landscape
Key players operating in the global renal biomarkers market include Beckman Coulter, Inc., (Danaher Corporation), Thermo Fisher Scientific Inc., Abbott Laboratories, BIOPORTO A/S, Astute Medical, Inc., Randox Laboratories Ltd., and SphingoTec GmbH.
Global Renal Biomarkers Market: Key Developments
January 2020: Hitado GmbH, a Sysmex point-of-care subsidiary, and SphingoTec GmbH signed an exclusive distribution agreement for the commercialization of the Nexus IB10 diagnostic platform, a fully automated rapid immunoassay point-of-care platform by Hitado, in Germany
October 2019: Antech Diagnostics acquired Biovet, a biotechnology company that offers diagnostic solutions for animal health
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/3551
- By Biomarker Type
- Functional Biomarker
- Serum Creatinine
- Serum Cystatin C
- Urine Albumin
- Up-Regulated Proteins
- Neutrophil gelatinase-associated lipocalin
- Kidney injury molecule 1
- Interleukin 18
- Functional Biomarker
- By Technique
- Enzyme-Linked Immunosorbent Assay
- Particle-Enhanced Turbidimetric Immunoassay
- Colorimetric Assay
- Chemiluminescent Enzyme Immunoassay
- Liquid Chromatography-Mass Spectrometry
- By End-User
- Diagnostic Labs
- Outpatient Clinics
- Research Centers
- By Region
- North America
- Latin America
- Asia Pacific
- Middle East
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3551
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire